Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 20/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 14/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2258419 | 0.94 | EPHX2 (0.91) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2260328 | 0.91 | EPHX2 (0.84) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2260145 | 0.90 | EPHX2 (0.83) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2259128 | 0.90 | EPHX2 (1.00) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2261596 | 0.90 | EPHX2 (0.83) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2259396 | 0.89 | EPHX2 (0.82) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2263070 | 0.89 | EPHX2 (0.81) | EPHX2CYP2C9 | |
| SCHEMBL2259931 | 0.88 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2261413 | 0.88 | EPHX2 (0.80) | EPHX2CYP2C9CYP3A4 | |
| SCHEMBL2260321 | 0.88 | EPHX2 (0.84) | EPHX2CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2209376-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-03-06 | — | — | EP | claimed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | claimed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | claimed |
| EP-2209376-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-07-28 | — | — | EP | claimed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | claimed |
| EP-2209376-B1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008483-B2 | sEH inhibitors and their use | GlaxoSmithKline, LLC (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2209376-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-07-28 | — | — | EP | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049165-A1 | NOVEL SEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210628-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, CYP46A1 | EPHX2 4/4885CYP2C9 160/4885CYP3A4 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.